In addition to MHC restriction, although we performed current proof-of-concept studies by delivering the heavy chain of MHC-I proteins (H-2Kb) to avoid immune escape caused by downregulated or lost expression of MHC-I molecules in tumor cells, it is worthwhile to consider the clinical significance of B2M in future studies because of its essential role in maintaining the stability of the MHC-I complex (Del Campo et al, 2014). This evidence concerns the gene B2M and neoplasm.